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SUMMARY 
Tumor necrosis factor (TNF) is an inflammatory cytokine that can signal cell survival or 
cell death. The mechanisms that switch between these distinct outcomes remain 
poorly defined. Here we show that the E3 ubiquitin ligase Mind Bomb-2 (MIB2) 
regulates TNF-induced cell death by inactivating RIPK1 via inhibitory ubiquitylation. 
While depletion of MIB2 has little effect on NF-B activation, it sensitizes cells to 
RIPK1- and caspase-8-dependent cell death. We find that MIB2 represses the cytotoxic 
potential of RIPK1 by ubiquitylating lysine residues in the C-terminal portion of RIPK1. 
Our data suggest that ubiquitin conjugation of RIPK1 interferes with RIPK1 
oligomerization and RIPK1-FADD association. Disruption of MIB2-mediated 
ubiquitylation, either by mutation of MIB2’s E3 activity or RIPK1’s ubiquitin-acceptor 
lysines, sensitizes cells to RIPK1-mediated cell death. Together, our findings 
demonstrate that Mind Bomb E3 ubiquitin-ligases can function as additional 
checkpoint of cytokine-induced cell death, selectively protecting cells from the 
cytotoxic effects of TNF.  
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INTRODUCTION 
TNF functions as a master regulator of the cytokine network that coordinates defense of 
homeostasis via controlling inflammation, cell proliferation, differentiation, survival and death 
(Balkwill, 2009). Ubiquitylation has emerged as a crucial mediator of signal transduction in 
inflammation, stress responses, and defense of homeostasis (Dikic et al., 2009). The 
formation of atypical Ubiquitin (Ub) chains produce robust signaling ‘hubs’ that are recognized 
by specialized Ub-binding proteins (Husnjak and Dikic, 2012), which subsequently coordinate 
tissue repair and adaptation to tissue stress. The signaling pathways emanating from TNF 
receptor-1 (TNF-R1) represent some of the best models to study the role of Ub in the 
regulation of homeostasis. In mammals, binding of TNF to TNF-R1 triggers either pro-
survival/inflammatory or pro-death signaling pathways (Walczak, 2013). TNF regulates tissue 
homeostasis by orchestrating three distinct signals: 1) The activation of NF-B-dependent 
and MAPK/JNK-dependent transcriptional programs, 2) induction of caspase-8-dependent 
apoptosis and 3) stimulation of Receptor interacting protein kinase (RIPK)-mediated necrosis 
(necroptosis) (Declercq et al., 2009).  
 
Binding of TNF to TNF-R1 results in the sequential formation of two signaling complexes 
(Walczak, 2011). The rapidly forming complex-I is assembled at the receptor’s cytoplasmic 
tail and consists of the adaptor TRADD, RIPK1, TRAF2, cIAP1 and cIAP2. Within this 
complex, RIPK1 and other proteins are rapidly conjugated with Ub chains of various types. 
Using Jurkat, L929 cells and MEFs, it was established that ubiquitylation of RIPK1 at K377 is 
indispensable for TNF-induced activation of NF-B (Ea et al., 2006; Grunert et al., 2012; 
Vanlangenakker et al., 2011; Zhang et al., 2011). Since then many additional studies have 
refined this view point, demonstrating that the requirement of RIPK1 for NF-B activation is 
cell type dependent (Blackwell et al., 2013; Suda et al., 2016; Wong et al., 2010). Together 
with LUBAC (linear ubiquitin chain assembly complex (Tokunaga et al., 2009)), complex-I 
signals inflammation and cell survival through TAK1 and IB kinase (IKK)-dependent 
activation of NF-B, which drives production of cytokines as well as pro-survival genes such 
as cFlip.  
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Through a process still ill defined, complex-I dissociates from the receptor, and RIPK1 
together with TRADD associates with the adaptor protein FADD and pro-caspase-8 (casp-8) 
to form complex-II (Micheau and Tschopp, 2003). The formation and activity of this signaling 
platform, which has the potential to initiate apoptosis or necroptosis, is tightly regulated by 
anti-apoptotic proteins such as cFLIP (Micheau et al., 2001; Panayotova-Dimitrova et al., 
2013). In addition, NEMO and TAK1 also act as regulators of TNF-induced cell death, partly 
independent of their role in NF-B activation (Bettermann et al., 2010; O'Donnell et al., 2007). 
The molecular mechanism underpinning the suppression of TNF-mediated complex-II 
formation is still poorly characterized. The current dogma dictates that ubiquitylation of RIPK1 
mediates activation of NF-B, cell survival and tissue repair, and its deubiquitylation, by de-
ubiquitylating enzymes (DUBs) such as CYLD, enhances complex-II formation and casp-8-
mediated apoptosis or necroptosis (Walczak, 2011). It is believed that the Ub chains 
conjugated to RIPK1 by cIAP1/2 and LUBAC in complex-I constitute the decisive factor 
preventing RIPK1 from forming complex-II, and limiting its killing potential (Bertrand et al., 
2008; Gerlach et al., 2011; Haas et al., 2009). However, this was recently challenged by the 
observations that formation of complex-II also occurs under conditions where cIAPs and 
LUBAC are fully functional, and following inhibition of TAK1 as well as loss of NEMO 
(Dondelinger et al., 2013; Kondylis et al., 2015; O'Donnell et al., 2007; O'Donnell and Ting, 
2011; Panayotova-Dimitrova et al., 2013). Under such conditions, complex-II assembles 
despite RIPK1 ubiquitylation in complex-I. We and others have also recently identified MK2 
as an additional checkpoint that regulates RIPK1 entry into complex-II. MK2 phosphorylates 
RIPK1 at Ser320 and Ser335 upon TNF stimulation to limit cell death downstream of TNF-R1  
(Dondelinger et al., 2017; Jaco et al., 2017; Menon et al., 2017).  
 
Because an inflammatory microenvironment can dictate the aggressiveness of certain 
tumors, and influence the response to therapy, a better understanding of the complex 
relationship between cell death and inflammation is critical. This is an important issue as its 
resolution, and putative therapeutic intervention, would allow the diversion of cancer-related 
inflammation into activation of cell death. Here we report that Mind Bomb E3 Ub-ligases 
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contribute to the regulation of TNF-induced cell death by inactivating RIPK1 via inhibitory 
ubiquitylation. 
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RESULTS 
Identification of MIB2 as a RIPK1-binding protein  
To elucidate what determines whether an inflammatory signal instructs either an innate 
immune response or triggers cell death, we undertook a proteomic-based approach using 
components of the TNF-R signaling complex (TNF-RSC) as affinity reagents. Proteins of the 
TNF-RSC were fused to 2x-HA tags and expressed in Flp-InTMT-RExTM-HEK293 cells that 
allow for single-copy insertion of these components under the control of doxycycline (Dox). 
HA-tagged proteins were purified and the presence of co-purified proteins was determined via 
mass spectrometry. In addition to known constituents of the native TNF-RSC, we identified 
the RING-type Ub-E3 ligase Mind Bomb-2 (MIB2) as a RIPK1-interacting protein (Figure 1A). 
Notably, MIB2 consistently co-purified with RIPK1 in six independent mass spectrometric 
experiments. We next verified the interaction of MIB2 with RIPK1 via co-immuno-precipitation, 
and demonstrated that MIB2 readily interacted with RIPK1 (Figure 1B). MIB1, which shares 
42% sequence homology with MIB2, also associated with RIPK1 under these conditions.  
 
MIB2 is a constituent of the native TNF-receptor signaling complex  
Consistent with the notion that MIB2 is part of complex-I, and in agreement with a recent 
mass spectrometry study (Wagner et al., 2016), we found that endogenous MIB2 was readily 
recruited to the TNF-RSC in a ligand- and time-dependent manner in a range of cell types, 
including MDA-MB-231, HT1080 and 786-0 (Figure 1C, 1D, and 1E). MIB2 recruitment was 
mainly RIPK1-dependent (Figure 1E), and occurred in the same dynamic manner as 
described for other components of complex-I (Gerlach et al., 2011; Haas et al., 2009; 
Micheau and Tschopp, 2003), peaking at 15 minutes. Reciprocal immuno-precipitation of 
endogenous MIB2, using MIB2-specific antibodies, likewise co-purified ubiquitylated RIPK1 
and other components of complex-I such as TRADD, TNF-R1 and SHARPIN, in a TNF- and 
time-dependent manner in multiple cell types (Figure 1F and 1G). This demonstrates that 
MIB2 is recruited to the initial complex-I that forms directly upon TNF stimulation. Although 
MIB2 is recruited to complex-I, our data indicated that, in the cell lines tested, MIB2 had no 
role in TNF-induced activation of NF-B, induction of NF-B target genes such as A20, and 
the production of cytokines (Figure S1A-G). 
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MIB2 protects cells from TNF-induced and RIPK1-dependent cell death 
Given that MIB2 did not modulate TNF-induced activation of NF-B in the cell lines tested, we 
explored the role of this E3 ligase in regulating TNF-induced and RIPK1-dependent cell 
death. We tested a range of different cell lines that exhibit diverse sensitivities to TNF-
induced cell death (Figure S2A-C) (Tenev et al., 2011; Vince et al., 2007). Specifically, we 
tested two paradigms of TNF-induced and RIPK1-dependent cell death, one that relies on the 
inhibition of TAK1, and one that occurs upon inactivation of IAPs with SMAC mimetic (SM) 
compounds. While many cells are sensitive to TNF in the presence of the TAK1 kinase 
inhibitor 5Z-7-Oxozeaenol (hereafter referred to as TAK1i), we focused our attention on a cell 
line that is largely resistant to this treatment combination, namely the renal cell 
adenocarcinoma 786-0. Intriguingly, depletion of MIB2, but not MIB1, dramatically sensitized 
786-0 cells to treatment with TNF in the presence of TAK1i, in both short-term cell death 
experiments and long-term clonogenic survival assays (Figure 2A-C and S2D). Cell death 
under these conditions was entirely RIPK1- and caspase-8-dependent as co-depletion of 
MIB2 and RIPK1 or CASPASE-8 protected cells from the cytotoxic effects of TNF/TAK1i, and 
treatment with z-VAD-FMK completely suppressed cell death, corroborating the notion that 
these cells die by apoptosis (Figure 2B and S2D). In agreement with MIB2 limiting RIPK1- 
and caspase-8-dependent apoptosis, formation of complex-II was also enhanced upon MIB2 
knockdown (Figure 2D, top panel, compare lane 9 with 10). MIB2 depletion also sensitized 
cells under conditions in which expression of NF-B target genes were blocked by expressing 
a dominant-negative form of IB (Super-Repressor, IBSR), and to a lesser extent upon 
treatment with cycloheximide (CHX) (Figure S2E and S2F). Moreover, CRISPR/Cas9-
mediated deletion of MIB1 and MIB2 also sensitized the triple negative breast cancer cell line 
MDA-MB-231 to TNF/TAK1i in a RIPK1-dependent manner (Figure 2E).  
 
SM compounds block IAP proteins and trigger cytokine-dependent apoptosis in cancer cells. 
However, only a subset of cancer cells appears to be sensitive to SM treatment, and even 
sensitive cells can develop resistance. We, therefore, established the role of MIB proteins in 
modulating the therapeutic potential of SM compounds. Intriguingly, RNAi-mediated depletion 
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or CRISPR/Cas9-mediated deletion of MIB2 significantly enhanced activation of caspase-8 
and the sensitivity of cells to TNF-induced cell death in the presence of SM in multiple cell 
types (Figure 2F-L). While RNAi-mediated knockdown of MIB2 exacerbated the cytotoxic 
effects of TNF/SM, depletion of MIB2 was somewhat sufficient to sensitize cells to TNF alone 
(Figure 2G and 2I). Interestingly, inhibiting the kinase activity of RIPK1 partially protected 
HT1080 and 786-0 cells from TNF-mediated cell death upon MIB2 depletion (Figure S2G and 
S2H). While the kinase activity of RIPK1 contributes to apoptosis in these cells, RIPK1’s 
scaffolding function seemed to play the predominant role as depletion or genetic deletion of 
RIPK1 blocks cell death in these cells (Figure 2B, 2E, 2F, 2H, 2K and S2K, S2L). Together, 
our data suggest that MIBs and IAPs both suppress TNF-dependent and RIPK1-mediated cell 
death.  
 
Depletion of MIB2 not only sensitized cells to exogenous TNF, but also to auto/paracrine 
TNF, produced in response to treatment with LPS that activates TLR4 and drives TLR4-
mediated and NF-B-dependent production of TNF (Figure 2K). Consistent with an increase 
in caspase activity (data not shown), we found that activation/cleavage of caspase-8 was 
enhanced upon knockdown of MIB2 under these conditions (Figure 2J and 2K). Additionally, 
we found that MIB2 co-purified with complex-II (Figure 2L). 
 
Some cells, such as the rhabdomyosarcoma cell line Kym1, were exclusively reliant on MIB2 
as mere knockdown of MIB2, using two independent siRNA oligos, induced cell death and 
loss of clonogenic growth potential (Figure S2I and S2J). Depletion of MIB2 resulted in 
RIPK1-mediated formation of complex-II and activation of caspase-8 (Figure S2K-L). Genetic 
deletion of TNF-R1 almost completely abrogated the sensitivity of Kym1 cells to depletion of 
MIB2 (Figure S2M). Together, these data indicate that MIB2 protects Kym1 cells from the 
cytotoxic potential of RIPK1.  
 
To address the role of MIB2 in regulating necroptosis, we used murine SWISS-3T3 cells that 
can die by apoptosis or necroptosis. Of note, all other cell lines used in our study do not 
express detectable levels of RIPK3, and hence are refractory to necroptosis triggers. While 
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depletion of Mib2 sensitized SWISS-3T3 cells to caspase-mediated and RIPK1 kinase-
dependent apoptosis upon treatment with TNF/SM, knockdown of Mib2 had no effect on 
necroptosis induced by TNF/SM/zVAD (Figure S2N-O). This suggests that, at least in 
SWISS-3T3 cells, MIB2 selectively regulates apoptosis. It is important to note that in these 
cells, TNF/SM-mediated activation of caspases requires RIPK1 kinase activity. This is evident 
as co-treatment with a selective RIPK1 kinase inhibitor blocks caspase activation upon 
TNF/SM treatment. 
 
MIB2 binds the linker region of oligomeric RIPK1 
Our data are consistent with the notion that MIB2 is a component of the TNF-RSC that 
contributes to the regulation of TNF-induced cell death. To further characterize the interaction 
of MIB2 with RIPK1 we generated a panel of deletion constructs for MIB2 (Figure 3A). We 
found that the N-terminal MZM region of MIB2 was necessary and sufficient for the interaction 
of MIB2 with RIPK1 (Figure 3B), and that deletion of the MZM region of MIB2 (Figure 3B), or 
mutation of the coordinating cysteine residue of the ZZ fold within the MZM region of MIB2 
(Figure 3C), abrogated the interaction with RIPK1. We next generated deletion constructs for 
RIPK1 and tested their ability to bind to MIB2’s MZM domain (Figure 3D). Of note, RIPK1 
oligomerization is mediated by either the RHIM or DD domain. Deletion of both these 
oligomerization domains is required to interfere with RIPK1 homo-oligomerization (Figure 
S3A-F). We found that combined deletion of RIPK1’s oligomerization surfaces (RHIM domain 
and DD, 1-510) abrogated the interaction of MIB2 with RIPK1 (Figure 3E). Deletion of either 
the DD domain (1-581) on its own, or removal of the RHIM in isolation (RHIM) had no effect 
on the binding (Figure 3E and 3F). While MIB2 did not bind to the kinase domain, it appeared 
to interact with the linker region of oligomerized RIPK1. Consistently, deletion of the linker 
region of RIPK1 abrogated MIB2 association (Figure 3F and Figure S3D). Recombinant MIB2 
and RIPK1 also bound to one another under in vitro conditions, indicating that this interaction 
is direct (Figure 3G and S3G). Under these conditions, in vitro translated RIPK1 oligomerized 
and was active (auto-phosphorylated at S166) (Figure S3H-J). Further, we found that in vitro 
translated MIB2 was capable of purifying RIPK1 from cellular extract, particularly following 
Feltham et al., 2018 
 10 
treatment with TNF/SM (Figure 3H). Taken together, our data suggest that MIB2 interacts 
with the linker region of oligomerized RIPK1 (Figure 3I).  
 
MIB2 prevents RIPK1-induced death in a RING- and binding-dependent manner 
While knockdown or genetic deletion of MIB2 sensitized cells to caspase-8-mediated cell 
death, reconstitution with wild-type MIB2 suppressed the cytotoxic effects of TNF, as 
measured by caspase-8 maturation, generation of caspase activity (DEVDase assay), PARP 
cleavage, formation of complex-II and viability assays (Figure 4A-F). Reconstitution with 
MIB2ZZ, which carries a mutation in the ZZ domain required for RIPK1 binding (Figure 4B, 4C 
and 4E), failed to suppress TNF-induced caspase activation and cell death. Importantly MIB2 
with an amino acid substitution of the second-last Phe residue (MIB2F>A) that abrogates its E3 
ligase activity, likewise failed to suppress TNF-induced cell death. Absence or mutational 
inactivation of MIB2 resulted in enhanced complex-II formation, caspase-8 activation and cell 
death. Hence, physical association between MIB2 and RIPK1 is necessary, but not sufficient 
to regulate RIPK1. This is evident because MIB2 RING finger mutants can still bind to RIPK1 
(Figure 3B) but fail to regulate RIPK1-mediated activation of caspase-8 and cell death (Figure 
4A-F). These data suggest that after binding, MIB2 inhibits RIPK1 through a mechanism that 
is dependent on the E3 ligase activity of MIB2.  
 
MIB2 ubiquitylates RIPK1 upon TNF stimulation independently of cIAPs 
Our data indicate that MIB2 is recruited to complex-I, and suppresses the cytotoxic effect of 
RIPK1 in a RING finger dependent manner. Consistent with the notion that RIPK1 is a 
physiological substrate of MIB2, we found that depletion or genetic deletion of MIB2 resulted 
in a reduction in ubiquitylation of RIPK1 in complex-I in both MDA-MB-231 and 786-0 cells 
(Figure 5A and S4A). Although RNAi-mediated depletion or genetic deletion of MIB2 resulted 
in reduced levels of ubiquitylated RIPK1 in complex-I, this had no apparent effect on the 
kinetics of the recruitment of other components of the TNF-RSC (Figure S4A), and neither 
affected TNF-induced activation of NF-B (Figure 5B and S4B). Of note, MDA-MB-231, 786-
0, and Kym-1 cells do not rely on RIPK1 for NF-B activation and cytokine production (Figure 
5B-C, S4B and S4D), corroborating the notion that the requirement of RIPK1 for NF-B 
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activation is cell type dependent (Blackwell et al., 2013; Suda et al., 2016; Wong et al., 2010). 
Moreover, RIPK1 is not required for ERK, p38 and JNK activation downstream of TNF in 786-
0 cells (Figure S4C). While RIPK1 is required for NF-B activation in Jurkat cells (Figure S4E, 
and (Ea et al., 2006)), we were unable to investigate the role of MIB2 in RIPK1-mediated 
signaling downstream of TNF in Jurkat cells because these cells do not survive long-term loss 
of MIB2, and are not sufficiently transfectable with siRNA oligos (data not shown). Following 
stimulation with TNF, MIB2 ubiquitylated RIPK1 in complex-I in a manner that was 
independent of IAPs. This is evident as the polyUb-smearing pattern of RIPK1 reproducibly 
increased in an IAP-independent yet MIB2-, TNF- and time-dependent manner (Figure 5D, 
5E and 5F). Using the reconstitution system described in Figure 4A, we examined the 
requirement of the RING finger of MIB2 to promote RIPK1 ubiquitylation. While wild-type 
MIB2 readily ubiquitylated RIPK1, the E3-Ub deficient MIB2 mutant MIB2F>A failed to 
ubiquitylate RIPK1 (Figure 5E and 5F). MIB2 also ubiquitylated RIPK1 with the help of 
UbcH5a in an in vitro ubiquitylation assay (Figure 5G and S4G). Although MIB1 also 
ubiquitylated RIPK1, it was somewhat less efficient than MIB2 (Figure S4F). 
 
MIB2 conjugates different types of Ub chains to RIPK1  
To determine the Ub linkage types that are conjugated to RIPK1 by MIBs, we used UbiCRest 
(Ub chain architecture using Ub chain restriction (Hospenthal et al., 2015)) analysis of RIPK1 
in complex-I in the presence and absence of MIB1/2. While the overall intensity of the 
ubiquitylation smearing pattern of RIPK1 was enhanced in the presence of endogenous MIB2 
(Figure 6A), there was no apparent change in the Ub linkage repertoire. Accordingly, 
incubation with the respective DUBs resulted in a reduction of the Ub smearing pattern, 
indicating that K11-, K48- and K63-linkage types were present. This demonstrates that K63-, 
K48- and K11-linked chains were present in both MIB1/2 proficient as well as deficient cells, 
but are more abundant when MIBs are present. This suggests that endogenous MIBs can 
conjugate K11-, K48- and K63-linked Ub chains to RIPK1. Using K-only Ub, we confirmed 
that MIB2 was indeed capable of conjugating K11-, K48- and K63-linked polyUb chains to 
RIPK1 (Figure 6B).  
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MIB2 ubiquitylates RIPK1 at multiple sites 
To identify the lysine (K) residue/s of RIPK1 that are ubiquitylated by MIB2 we used a semi-
quantitative mass spectrometry-based approach. In total, 14 K residues of RIPK1 were found 
to be modified by Ub (Figure 6C). These included previously reported K residues (green dots) 
(Ofengeim and Yuan, 2013) as well as several additional ubiquitylation sites on RIPK1 
(yellow) (Figure 6C). The identified K residues of RIPK1 clustered into three regions: i) kinase 
domain, ii) region surrounding K377, and iii) death domain (DD). Of the Ub-modified K 
residues, only 4 sites were specifically enriched by MIB2WT versus MIB2F>A (K316, K571, 
K604, and K634) (Figure 6D). K377 of human RIPK1, previously reported to be crucial for 
TNF induced cell death (Ea et al., 2006; Li et al., 2006; O'Donnell et al., 2007), was not 
detected by mass spectrometry because the tryptic digest generates peptide fragments that 
are too long for analysis. To address this issue, we conducted targeted mass spectrometry 
using double-digestion with Trypsin and GluC. While this approach successfully identified 
K377 of human RIPK1 as being ubiquitylated (Figure 6E), this approach did not allow 
accurate quantification of this ubiquitylation event. Whereas MIB2 readily ubiquitylated wild-
type RIPK1, mutating K377 to R significantly reduced MIB2-mediated ubiquitylation of RIPK1 
(Figure S5A). As expected, the ability of MIB2 to ubiquitylate K377 was critically dependent 
on MIB2’s own RING finger activity as the E3-deficient MIB2F>A mutant failed to ubiquitylate 
RIPK1 (Figure S5A). While RIPK1K377R was less ubiquitylated in complex-I (Figure 6F), this 
mutant was significantly more auto-phosphorylated at S166 (Figure 6G). This indicates that 
ubiquitylation at K377 represses RIPK1’s kinase activity. RIPK1K377R interacted with MIB2 as 
efficiently as RIPK1WT, indicating that deregulation of RIPK1K377R was not due to impaired 
MIB2-binding (Figure S5B).  
 
MIB2-mediated ubiquitylation of K377 and K634 suppresses RIPK1’s cytotoxic 
potential 
Of the identified residues, K604 and K634 are positioned at the interface between two RIPK1 
DD (type-I and -II interfaces) (Figure 7A-D). Given their position, ubiquitylation of these 
residues is predicted to affect RIPK1 self-association. K634 also locates between RIPK1’s DD 
and FADD’s DD (type-II interface), which is predicted to directly affect the interaction if 
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ubiquitylated. Consistent with the structural prediction, we found that reconstituted RIPK1K634R 
cells were considerably more sensitive than RIPK1WT cells when challenged with TNF/TAK1i 
(Figure 7E, 7F and S6). RIPK1K634R was as cytotoxic as RIPK1K377R, indicating that 
ubiquitylation of either of these two sites represses the killing potential of RIPK1. Consistent 
with the notion that MIB2 regulates RIPK1 by targeting multiple K residues, depletion of MIB2 
further reduced ubiquitylation of RIPK1K634R and RIPK1K377R (Figure S7A and S7B), and 
further sensitized RIPK1K377R cells to TNF killing (Figure 7G). Together, these data indicate 
that MIB2 antagonizes the lethal effects of TNF by attaching Ub chains to the linker and C-
terminal portion of RIPK1, thereby skewing TNF’s signaling potential towards pro-survival and 
pro-inflammation rather than cell death.  
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DISCUSSION 
Ub-mediated inactivation of RIPK1 has long been postulated to contribute to the regulation of 
cytokine-induced cell death (Ea et al., 2006; Moquin et al., 2013; O'Donnell et al., 2007). 
cIAP- and LUBAC-mediated ubiquitylation of RIPK1 are decisive factors in limiting the 
formation of complex-II (Bertrand et al., 2008; Gerlach et al., 2011; Haas et al., 2009). In the 
absence of either cIAPs or LUBAC or inhibition of the TAK1-IKKß axis, TNF fails to activate 
canonical NF-κB effectively, and consequently, the levels of NF-κB target genes that limit 
complex-II activity, such as cFLIPL, are insufficient to prevent caspase-8-mediated cell death. 
Primarily this occurs via the induction of NF-κB and the upregulation of cFLIP, however, 
recent evidence suggests that TAK1 and IKK can regulate TNF killing independent of their 
role in NF-κB activation (Bettermann et al., 2010; Dondelinger et al., 2015; O'Donnell et al., 
2007). In the absence of functional TAK1 and IKK, lethal levels of complex-II assemble 
despite RIPK1 ubiquitylation in complex-I (Dondelinger et al., 2013; Dondelinger et al., 2015; 
Legarda-Addison et al., 2009). Under these conditions, TNF-mediated RIPK1-dependent 
apoptosis was shown to rely on the kinase activity of RIPK1 (Dondelinger et al., 2013; Wang 
et al., 2008). Thus, cells regulate TNF-induced cell death through multiple mechanisms. 
 
Here we have identified MIB2 as an E3 ligase that can regulate TNF killing. We find that it 
selectively regulates TNF-induced cell death, while it plays no role in NF-B activation in the 
systems tested. MIB2 directly binds to RIPK1 and conjugates inhibitory Ub chains to the linker 
and the C-terminal portion of RIPK1. While it remains to be determined how ubiquitylation of 
K377 suppresses RIPK1 kinase activity (auto-phosphorylation), ubiquitylation of K604 and 
K634 is predicted to affect RIPK1 self-association as these residues are positioned at the 
interface between two RIPK1 death domains. Moreover, K634 is located between RIPK1’s 
DD and FADD’s DD, which is predicted to directly affect the interaction if ubiquitylated.  
 
Different cells have different sensitivities to modulation of cIAPs and MIB2. Some cells are 
acutely sensitive to TNF-induced cell death in the absence of cIAPs or MIB2, while others are 
not. Consistently, while RNAi-mediated knockdown of MIB2 exacerbates the cytotoxic effects 
of TNF/SM, depletion of MIB2 is sufficient to sensitize certain cells to TNF alone (Figure 2G 
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and 2I). The efficiency with which TNF/siMIB2 induces cell death is comparable to the one 
triggered by TNF/SM (Figure 2G and 2I). As cIAPs not only control TNF killing, but also are 
key mediators of TNF-induced activation of NF-B and the expression of pro-survival genes 
(Silke and Meier, 2013), their role clearly extends beyond simple regulation of RIPK1’s 
cytotoxic potential. In contrast, MIB2 appears to exclusively inhibit RIPK1’s killing potential. 
The notion that MIB2 contributes to the resistance to RIPK1-mediated cell death is also 
supported by the observation that high levels of MIB2 inhibit cell death triggered by TNF, SM, 
TNF/SM or TNF/TAK1i. Since pharmacological inhibitors of IAPs are in clinical testing, our 
data suggest that targeting the MIB2 Ub ligase might improve the efficacy of SMs for the 
treatment of cancer. However, it should be noted that resistance to SM treatment can occur in 
multiple ways. While levels of MIB2 clearly matter with regards to SM sensitivity, cells can 
also become resistant to SM by loss of autocrine-TNF, TNF-R1, RIPK1, FADD, caspase-8 
and other mechanisms.  
 
The importance of the E3 ligase activity of MIB2 in regulating RIPK1, and TNF-induced cell 
death, is highlighted by MIB2 variants bearing RING mutations. The ability of MIB2 to protect 
from the cytotoxic effects of TNF is strictly dependent on MIB2 neutralizing RIPK1 in a 
binding- and Ub-dependent manner. MIB2 mutations that selectively abrogate binding or 
ubiquitylation of RIPK1 cause loss of MIB2 function. The ability of MIB2 to bind to RIPK1 
depends on activation of TNF-R1. This may be due to the fact that TNF-mediated clustering 
of TNF-R1 results in oligomerization of RIPK1, which in turn is essential for MIB2 to bind and 
ubiquitylate RIPK1. In the absence of TNF-R1 activation, MIB2 does not associate with 
RIPK1, potentially because HSP90 sequesters RIPK1 in its monomeric, kinase inactive state 
(Lewis et al., 2000). Thus, under resting conditions, RIPK1 seems to reside in an inactive 
configuration that precludes MIB2 binding. Only when it is recruited to TNF-R1 can it bind 
tightly to MIB2. In this respect, MIB2 may sense the activity status of RIPK1. This is similar to 
cIAPs, which also only regulate RIPK1 upon cytokine stimulation (Varfolomeev et al., 2007; 
Vince et al., 2007).  
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The question remains why there is an apparent overlap in the functions of MIB2 and cIAPs.  
One possible scenario might be that MIB2 and cIAPs target different K residues of RIPK1. It 
is interesting that MIB2 preferentially ubiquitylates the linker and the C-terminal portion of 
RIPK1, while other E3 ligases prefer to ubiquitylate the kinase domain (Figure 6C), albeit 
TRAF2/cIAPs also reportedly ubiquitylate K377 (O'Donnell et al., 2007), which seems to be a 
prominent Ub acceptor K. MIB2-mediated ubiquitylation of RIPK1 appears to interfere with 
RIPK1 oligomerisation (DD-DD interactions), while cIAP-dependent RIPK1 ubiquitylation may 
suppress its kinase activity, which is required for complex-II formation in some cell types 
(Dondelinger et al., 2013; Wang et al., 2008). 
 
Together, our data demonstrate that MIB2 contributes to inhibiting the pro-apoptotic activity of 
RIPK1. While MIB2 is clearly not the only E3 ligase that can target RIPK1 for ubiquitylation, it 
is unique in its ability to selectively limit TNF-induced killing without affecting activation of 
TAK1, IKK, p38, JNK and NF-B in our system. Other E3 ligases in complex-I, such as cIAPs 
or LUBAC influence TAK1 and IKK activation. Through ubiquitylation of RIPK1, MIB2 seems 
to consolidate the ubiquitylation status of RIPK1 in complex-I, thereby suppressing its 
transition to complex-II. The absence of MIB2, therefore, specifically converts the 
predominant survival signal that originates from TNF-R1 into a death signal, a situation that 
might be relevant upon viral infection (pattern recognition receptor activation) or engagement 
of multiple cytokine receptors (Geserick et al., 2009; Tenev et al., 2011).  
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EXPERIMENTAL PROCEDURES   
Further details and an outline of resources used in this work can be found in Supplemental 
Experimental Procedures.  
 
Cell Culture  
HT1080IkB-SR, Kym1, HT1080, MDA-MB-231, Jurkat, SWISS-3T3, HEK293T and Flp-InTMT-
RExTM-HEK293 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM). 786-0 
were cultured in RPMI-1640 medium. Culture media were supplemented with 10% fetal 
bovine serum (Gibco), penicillin and streptomycin (Gibco) and all cells were cultured at 37°C 
with 10% CO2 in a humidified incubator. 
 
Generation of CRISPR Cells  
Guide RNAs were designed according to the Church lab (Mali et al., 2013) or Zhang lab (Ran 
et al., 2013). Prior to CRISPR-Cas9 editing, cells were FACS-sorted and single clones were 
isolated and characterized. Single cell clones were then transfected with Cas9 and gRNA 
targeting the gene of interest using Invitrogen reagents. Three days after transfection cells 
were FACS sorted and single clones were isolated and screened for the deletion of the gene 
of interest. MIB2 knockout clones or were further used to generate MIB1/2 knockout cells. 
Positive clones were characterized. Guide sequences are available upon request. 
 
Immuno-Precipitation Assays 
Immuno-Precipitation assays were performed as previously described (Jaco et al., 2017). For 
all immuno-precipitation assays cells were treated as indicated and lysed on ice in DISC lysis 
buffer supplemented with protease inhibitors. Cell lysates were rotated at 4 °C for 20 mins 
then clarified at 4 °C at 14,000 rpm for 10 mins. 20 μl of anti-FLAG M2 beads (SIGMA), 20 μl 
of anti-HA beads (SIGMA) or 20 μl of protein A/G agarose (Pierce) + MIB2 antibody (Bethyl 
Laboratories) or RIPK1 BD antibody; 1 μg antibody/mg protein lysate were rotated with 
cleared protein lysates overnight at 4 °C. 4x washes in wash buffer (50 mM Tris pH 7.5, 150 
mM NaCl, 0.1% Triton X-100, and 5% glycerol) were performed, and samples eluted by 
boiling in 50 μl 1x SDS loading dye. 
  
Statistics 
Statistical analysis was performed using GraphPad Prism V6.0. Unless otherwise specified, 
data are presented as mean ± SEM. Comparisons were performed with a Student’s t test 
whose values are represented in the figures as *p < 0.05, **p < 0.01, and ***p < 0.001. 
 
ACKNOWLEDGEMENTS 
We would like to thank Henning Walczak, Freddy Radtke, Shaomeng Wang, Patricia J. 
Gallagher, Vanessa Redecke, Katrin Rittinger and Ivan Dikic for reagents and advice. We 
Feltham et al., 2018 
 18 
also thank members of the Komander and Meier labs for helpful discussions. We would like to 
apologize to the many authors whose work we could not cite due to space restrictions. Work 
in the Meier lab is funded by Breast Cancer Now (CTR-QR14-007), Medical Research 
Council (MRC) (MR/M019217/1), Komen Promise (PG12220321), Worldwide Cancer 
Research (15-0042), Biotechnology and Biological Sciences Research (BBSRC) 
(BB/L021684/1) and postgraduate studentships from Cancer Research UK (CRUK) 
(CRM089X). The Martin laboratory is supported by PI (08/IN.1/B2031) and SRC 
(07/SRC/B1144) grants from Science Foundation Ireland. C.J.K. was supported by an 
IRCSET postgraduate studentship (RS/2010/2542). The Nesvizhskii is supported by the 
National Institute of Health (GM094231 and CA126239). The Wu lab is funded by the 
National Institute of Health (AI050872 to H.W). Work in the D.K. lab is funded by MRC 
(U105192732), the European Research Council (724804), and the Lister Institute of 
Preventive Medicine. We acknowledge NHS funding to the NIHR Biomedical Research 
Centre. 
 
 
AUTHOR CONTRIBUTIONS 
P.M., R.F., K.J. and T.T., designed the research and wrote the manuscript. R.F., K.J., T.T., 
performed experiments. G.L. performed the PLA assay, I.J. performed some death assays, 
O.M. and C.M.D. conducted preliminary experiments using Drosophila melanogaster, S.W.J. 
performed the Y2H assay, and A.A, T.G., A.N. A.S., M.W. and A.J.T. conducted the mass 
spectrometry analysis. C.K., D.C., S.M., conducted the cytokine analysis. A.A, P.R.E and 
D.K. helped with the UbiCRest analysis. Q.Q. and H.W. did the structural homology model.  
  
 
Declaration of Interests 
 
The authors declare no competing interests. 
 
 
  
Feltham et al., 2018 
 19 
REFERENCES 
Balkwill, F. (2009). Tumour necrosis factor and cancer. Nat Rev Cancer 9, 361-371. 
Bertrand, M.J., Milutinovic, S., Dickson, K.M., Ho, W.C., Boudreault, A., Durkin, J., Gillard, 
J.W., Jaquith, J.B., Morris, S.J., and Barker, P.A. (2008). cIAP1 and cIAP2 facilitate cancer 
cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 30, 689-
700. 
Bettermann, K., Vucur, M., Haybaeck, J., Koppe, C., Janssen, J., Heymann, F., Weber, A., 
Weiskirchen, R., Liedtke, C., Gassler, N., et al. (2010). TAK1 suppresses a NEMO-dependent 
but NF-kappaB-independent pathway to liver cancer. Cancer Cell 17, 481-496. 
Blackwell, K., Zhang, L., Workman, L.M., Ting, A.T., Iwai, K., and Habelhah, H. (2013). Two 
coordinated mechanisms underlie tumor necrosis factor alpha-induced immediate and 
delayed IkappaB kinase activation. Mol Cell Biol 33, 1901-1915. 
Declercq, W., Vanden Berghe, T., and Vandenabeele, P. (2009). RIP kinases at the 
crossroads of cell death and survival. Cell 138, 229-232. 
Dikic, I., Wakatsuki, S., and Walters, K.J. (2009). Ubiquitin-binding domains - from structures 
to functions. Nat Rev Mol Cell Biol 10, 659-671. 
Dondelinger, Y., Aguileta, M.A., Goossens, V., Dubuisson, C., Grootjans, S., Dejardin, E., 
Vandenabeele, P., and Bertrand, M.J. (2013). RIPK3 contributes to TNFR1-mediated RIPK1 
kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell 
Death Differ 20, 1381-1392. 
Dondelinger, Y., Delanghe, T., Rojas-Rivera, D., Priem, D., Delvaeye, T., Bruggeman, I., Van 
Herreweghe, F., Vandenabeele, P., and Bertrand, M.J.M. (2017). MK2 phosphorylation of 
RIPK1 regulates TNF-mediated cell death. Nat Cell Biol 19, 1237-1247. 
Dondelinger, Y., Jouan-Lanhouet, S., Divert, T., Theatre, E., Bertin, J., Gough, P.J., 
Giansanti, P., Heck, A.J., Dejardin, E., Vandenabeele, P., et al. (2015). NF-kappaB-
Independent Role of IKKalpha/IKKbeta in Preventing RIPK1 Kinase-Dependent Apoptotic and 
Necroptotic Cell Death during TNF Signaling. Mol Cell 60, 63-76. 
Ea, C.K., Deng, L., Xia, Z.P., Pineda, G., and Chen, Z.J. (2006). Activation of IKK by 
TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. 
Mol Cell 22, 245-257. 
Gerlach, B., Cordier, S.M., Schmukle, A.C., Emmerich, C.H., Rieser, E., Haas, T.L., Webb, 
A.I., Rickard, J.A., Anderton, H., Wong, W.W., et al. (2011). Linear ubiquitination prevents 
inflammation and regulates immune signalling. Nature 471, 591-596. 
Geserick, P., Hupe, M., Moulin, M., Wong, W.W., Feoktistova, M., Kellert, B., Gollnick, H., 
Silke, J., and Leverkus, M. (2009). Cellular IAPs inhibit a cryptic CD95-induced cell death by 
limiting RIP1 kinase recruitment. J Cell Biol 187, 1037-1054. 
Grunert, M., Gottschalk, K., Kapahnke, J., Gundisch, S., Kieser, A., and Jeremias, I. (2012). 
The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-kappaB by 
TRAIL. Cell Death Dis 3, e414. 
Haas, T.L., Emmerich, C.H., Gerlach, B., Schmukle, A.C., Cordier, S.M., Rieser, E., Feltham, 
R., Vince, J., Warnken, U., Wenger, T., et al. (2009). Recruitment of the linear ubiquitin chain 
assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated 
gene induction. Mol Cell 36, 831-844. 
Hospenthal, M.K., Mevissen, T.E., and Komander, D. (2015). Deubiquitinase-based analysis 
of ubiquitin chain architecture using Ubiquitin Chain Restriction (UbiCRest). Nature protocols 
10, 349-361. 
Husnjak, K., and Dikic, I. (2012). Ubiquitin-binding proteins: decoders of ubiquitin-mediated 
cellular functions. Annu Rev Biochem 81, 291-322. 
Jaco, I., Annibaldi, A., Lalaoui, N., Wilson, R., Tenev, T., Laurien, L., Kim, C., Jamal, K., 
Wicky John, S., Liccardi, G., et al. (2017). MK2 Phosphorylates RIPK1 to Prevent TNF-
Induced Cell Death. Mol Cell 66, 698-710 e695. 
Kondylis, V., Polykratis, A., Ehlken, H., Ochoa-Callejero, L., Straub, B.K., Krishna-
Subramanian, S., Van, T.M., Curth, H.M., Heise, N., Weih, F., et al. (2015). NEMO Prevents 
Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated 
Hepatocyte Apoptosis. Cancer Cell 28, 582-598. 
Legarda-Addison, D., Hase, H., O'Donnell, M.A., and Ting, A.T. (2009). NEMO/IKKgamma 
regulates an early NF-kappaB-independent cell-death checkpoint during TNF signaling. Cell 
Death Differ 16, 1279-1288. 
Lewis, J., Devin, A., Miller, A., Lin, Y., Rodriguez, Y., Neckers, L., and Liu, Z.G. (2000). 
Disruption of hsp90 function results in degradation of the death domain kinase, receptor-
Feltham et al., 2018 
 20 
interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-
kappaB activation. J Biol Chem 275, 10519-10526. 
Li, H., Kobayashi, M., Blonska, M., You, Y., and Lin, X. (2006). Ubiquitination of RIP is 
required for tumor necrosis factor alpha-induced NF-kappaB activation. J Biol Chem 281, 
13636-13643. 
Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E., and Church, 
G.M. (2013). RNA-guided human genome engineering via Cas9. Science 339, 823-826. 
Menon, M.B., Gropengiesser, J., Fischer, J., Novikova, L., Deuretzbacher, A., Lafera, J., 
Schimmeck, H., Czymmeck, N., Ronkina, N., Kotlyarov, A., et al. (2017). p38MAPK/MK2-
dependent phosphorylation controls cytotoxic RIPK1 signalling in inflammation and infection. 
Nat Cell Biol 19, 1248-1259. 
Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K., and Tschopp, J. (2001). NF-kappaB 
signals induce the expression of c-FLIP. MolCell Biol 21, 5299. 
Micheau, O., and Tschopp, J. (2003). Induction of TNF receptor I-mediated apoptosis via two 
sequential signaling complexes. Cell 114, 181-190. 
Moquin, D.M., McQuade, T., and Chan, F.K. (2013). CYLD deubiquitinates RIP1 in the 
TNFalpha-induced necrosome to facilitate kinase activation and programmed necrosis. PLoS 
One 8, e76841. 
O'Donnell, M.A., Legarda-Addison, D., Skountzos, P., Yeh, W.C., and Ting, A.T. (2007). 
Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF 
signaling. Curr Biol 17, 418-424. 
O'Donnell, M.A., and Ting, A.T. (2011). RIP1 comes back to life as a cell death regulator in 
TNFR1 signaling. Febs J 278, 877-887. 
Ofengeim, D., and Yuan, J. (2013). Regulation of RIP1 kinase signalling at the crossroads of 
inflammation and cell death. Nat Rev Mol Cell Biol 14, 727-736. 
Panayotova-Dimitrova, D., Feoktistova, M., Ploesser, M., Kellert, B., Hupe, M., Horn, S., 
Makarov, R., Jensen, F., Porubsky, S., Schmieder, A., et al. (2013). cFLIP regulates skin 
homeostasis and protects against TNF-induced keratinocyte apoptosis. Cell reports 5, 397-
408. 
Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome 
engineering using the CRISPR-Cas9 system. Nature protocols 8, 2281-2308. 
Silke, J., and Meier, P. (2013). Inhibitor of apoptosis (IAP) proteins-modulators of cell death 
and inflammation. Cold Spring Harbor perspectives in biology 5. 
Suda, J., Dara, L., Yang, L., Aghajan, M., Song, Y., Kaplowitz, N., and Liu, Z.X. (2016). 
Knockdown of RIPK1 Markedly Exacerbates Murine Immune-Mediated Liver Injury through 
Massive Apoptosis of Hepatocytes, Independent of Necroptosis and Inhibition of NF-kappaB. 
J Immunol. 
Tenev, T., Bianchi, K., Darding, M., Broemer, M., Langlais, C., Wallberg, F., Zachariou, A., 
Lopez, J., MacFarlane, M., Cain, K., et al. (2011). The Ripoptosome, a signaling platform that 
assembles in response to genotoxic stress and loss of IAPs. Mol Cell 43, 432-448. 
Tokunaga, F., Sakata, S., Saeki, Y., Satomi, Y., Kirisako, T., Kamei, K., Nakagawa, T., Kato, 
M., Murata, S., Yamaoka, S., et al. (2009). Involvement of linear polyubiquitylation of NEMO 
in NF-kappaB activation. Nat Cell Biol 11, 123-132. 
Vanlangenakker, N., Bertrand, M.J., Bogaert, P., Vandenabeele, P., and Vanden Berghe, T. 
(2011). TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex 
I and II members. Cell Death Dis 2, e230. 
Varfolomeev, E., Blankenship, J.W., Wayson, S.M., Fedorova, A.V., Kayagaki, N., Garg, P., 
Zobel, K., Dynek, J.N., Elliott, L.O., Wallweber, H.J., et al. (2007). IAP antagonists induce 
autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 
131, 669-681. 
Vince, J.E., Wong, W.W., Khan, N., Feltham, R., Chau, D., Ahmed, A.U., Benetatos, C.A., 
Chunduru, S.K., Condon, S.M., McKinlay, M., et al. (2007). IAP antagonists target cIAP1 to 
induce TNFalpha-dependent apoptosis. Cell 131, 682-693. 
Wagner, S.A., Satpathy, S., Beli, P., and Choudhary, C. (2016). SPATA2 links CYLD to the 
TNF-alpha receptor signaling complex and modulates the receptor signaling outcomes. 
EMBO J 35, 1868-1884. 
Walczak, H. (2011). TNF and ubiquitin at the crossroads of gene activation, cell death, 
inflammation, and cancer. Immunol Rev 244, 9-28. 
Walczak, H. (2013). Death receptor-ligand systems in cancer, cell death, and inflammation. 
Cold Spring Harbor perspectives in biology 5, a008698. 
Feltham et al., 2018 
 21 
Wang, L., Du, F., and Wang, X. (2008). TNF-alpha induces two distinct caspase-8 activation 
pathways. Cell 133, 693-703. 
Wong, W.W., Gentle, I.E., Nachbur, U., Anderton, H., Vaux, D.L., and Silke, J. (2010). RIPK1 
is not essential for TNFR1-induced activation of NF-kappaB. Cell Death Differ 17, 482-487. 
Zhang, J., Zhang, H., Li, J., Rosenberg, S., Zhang, E.C., Zhou, X., Qin, F., and Farabaugh, 
M. (2011). RIP1-mediated regulation of lymphocyte survival and death responses. Immunol 
Res 51, 227-236. 
 
  
Feltham et al., 2018 
 22 
FIGURE LEGENDS 
Figure 1. Identification of MIB2 as a novel component of TNF receptor complex-I 
(A) Schematic representation of the RIPK1-bound target proteins that were identified by mass 
spectrometry. The table specifies the sum of the spectral counts across six independent 
immuno-precipitations for each target protein with a minimum SAINT score probability of 0.86. 
(B) HA-GFP, HA-MIB1 or HA-MIB2 was co-expressed with untagged RIPK1 in 293T cells. 
HA-immuno-precipitation was performed and RIPK1 interaction was assessed via western 
blot. 
(C-E) TNF-induced complex-I immuno-precipitation. MDA-MB-231 cells (C) or HT1080 cells 
(D) or WT 786-0 or RIPK1 KO 786-0 cells (E) were treated with FLAG-hTNF (0.8g/ml) for 
the indicated time points, followed by FLAG immuno-precipitation and western blot analysis. 
(F-G) Western blot analysis of MDA-MB-231 cells (F) or 786-O cells (G) either left untreated 
or treated with FLAG-hTNF (0.8 μg/ml) for the indicated time points followed by MIB2 
immuno-precipitation.  
 
Figure 2. Depletion of MIB2 sensitizes cells to TNF-induced and RIPK1-dependent cell 
death 
(A) FACS analysis of PI positive 786-0 cells subjected to siRNA knockdown of MIB2. After 
siRNA knockdown cells were treated with the indicated agents for 48 hours. Error bars 
represent SD.   
(B) FACS analysis of PI positive 786-0 cells subjected to siRNA knockdown of indicated 
genes. After siRNA knockdown cells were treated with the indicated agents for 48 hrs. Error 
bars represent SD.   
(C) Clonogenic growth assay of 786-0 cells subjected to siRNA knockdown of indicated 
genes. 40 hrs post siRNA, 1000 cells were re-plated, treated with TNF/TAK1i and left in 
treated medium to form colonies. Error bars represent SEM. Western blot analysis 
corresponding to Figure 2C of 786-0 cells subjected to MIB1, MIB2 or MIB1/2 knockdown. 
(D) Immuno-precipitation of complex-II following TNF stimulation. Cells were pre-treated with 
TAK1i and zVAD for 1 hr (zVAD and TAK1i also added to 0 hr) followed by treatment with 
FLAG-hTNF (0.8 µg/ml) for the indicated time points. Caspase-8 immuno-precipitation was 
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performed followed by western blot analysis. Quantification of RIPK1 bound to caspase-8 is 
shown. 
(E) FACS analysis of PI positive MIB1/2 DKO MDA-MB-231 cells subjected to siRNA 
knockdown of RIPK1 followed by treatment with TNF (10 ng/ml) or TAK1i (1 µM) alone or in 
combination for 16 hrs. Error bars represent SD. 
(F) Western blot analysis of activated caspase-8 (P41/43 cleavage product) following siRNA-
mediated knockdown of CTRL, RIPK1 or MIB2 in HT1080 cells and treatment with TNF/SM 
for 3 hrs.    
(G) FACS analysis of PI/AnnexinV positive HT1080 cells subjected to siRNA knockdown of 
the indicated genes followed by treatment with TNF (10 ng/ml) or SM (100 nM) alone or in 
combination for 6 hrs. Error bars represent SEM. 
(H) FACS analysis of PI positive MIB1/2 DKO or RIPK1 KO MDA-MB-231 cells treated with 
SM (100 nM) for 16 hrs. Error bars represent SD. 
(I) FACS analysis of PI positive 786-0 cells treated with TNF (10 ng/ml) or SM (100 nM) or in 
combination for 48 hrs. 
(J) MTT-cell viability assay of MDA-MB-231 cells subjected to siRNA-mediated knockdown of 
MIB2. After siRNA-mediated knockdown cells were treated with SM (100 nM) or LPS (10 
μg/ml) alone or in combination for 3 hrs. Error bars represent SD. 
(K) Western blot analysis of activated caspase-8 (P41/43 cleavage product) following siRNA-
mediated knockdown of CTRL, RIPK1 or MIB2 in MDA-MB-231 cells and treatment with 
LPS/SM for 4.5 hrs.  
(L) TNF-induced complex-II immuno-precipitation. MDA-MB-231 cells were treated with the 
indicated agents for 4 hrs. Caspase-8 immuno-precipitation was performed followed by 
western blot analysis. An asterisk indicates cross reactive bands. 
 
Figure 3. MZM domain of MIB2 is required for binding to oligomeric RIPK1 
(A) Domain organization of MIB2. The MZM, REP, ANK and RING regions of the protein are 
indicated. The numbers depict the position of the amino acid of the indicated deletion 
constructs used.  
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(B) HA-MIB2 deletion constructs were co-expressed with untagged RIPK1 in 293T cells. HA-
immuno-precipitation was performed and RIPK1 interaction was assessed via western blot.  
(C) HA-vector control, HA-MIB2WT or HA-MIB2ZZ (carrying a single point mutation in the ZZ-
domain) was co-expressed with untagged RIPK1 in 293T cells. HA-immuno-precipitation was 
performed and RIPK1 interaction was assessed via western blot. 
(D) Schematic representation of RIPK1 constructs used in the binding studies. 
(E-F) HA-RIPK1 deletion constructs were co-expressed with FLAG-MIB2 MZM domain in 
293T cells. HA-immuno-precipitation was performed and interaction with MIB2 MZM was 
assessed via western blot.  
(G) In vitro binding assay with recombinant MIB2 and in vitro translated RIPK1.  
(H) Binding assay with MIB2 (in vitro translated) and RIPK1 (from cellular extract). MDA-MB-
231 cells were left untreated or treated with TNF/SM/zVAD-fmk for 4 hrs and lysates were 
incubated with in vitro translated FLAG-MIB2.  
(I) Schematic representation of the interaction between MIB2 and oligomerized RIPK1. 
 
Figure 4. MIB2 protects cells to TNF-induced and RIPK1-dependent cell death, in a 
RING and RIPK1-binding dependent manner 
(A) Schematic diagram of the reconstitution system using MDA-MB-231 cells. Doxycycline 
treatment induces simultaneous knockdown of endogenous MIB2 and expression of shRNA 
resistant wildtype MIB2, MIB2ZZ, MIB2F>A or RFP. TRE, tetracyclin response element; UBC, 
ubiquitin promoter; rtTA3, reverse Tet transactivator. 
(B-C) MTT-cell viability assay of the indicated stable cells following induction of the target 
genes with Doxycycline (500 ng/ml) for 64 hrs, and treatment with TNF (10 ng/ml) + SM (100 
nM) for 3 hrs (B) or with LPS (10 μg/ml) + SM (100 nM) for 5 hrs (C). Error bars represent SD. 
(D) Western blot analysis of activated caspase-8 (P41/43 cleavage product) using stable cells 
described in. Cells were induced for 64 hrs with 500 ng/ml of Doxycycline and treated +/- LPS 
(10 μg/ml) + SM (100 nM) for 5 hrs.  
(E) DEVDase activity analysis using stable cells described in. Cells were induced for 64 hrs 
with 500 ng/ml of Doxycycline and treated with LPS (10 μg/ml) or SM (100 nM) alone or in 
combination for 3 hrs. Error bars represent SD. 
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(F) TNF-induced complex-II immuno-precipitation. Stable cells described in were induced with 
doxycycline for 64 hrs and treated with the indicated agents for 4 hrs. Caspase-8 immuno-
precipitation was performed followed by western blot analysis.  
 
Figure 5. MIB2 ubiquitylates RIPK1 in a TNF dependent manner 
(A) TNF-induced complex-I immuno-precipitation depicting the ubiquitylation of RIPK1. WT 
and MIB1/2 DKO MDA-MB-231 cells were treated with FLAG-TNF (0.8g/ml) for the 
indicated time-points, followed by FLAG immuno-precipitation and western blot analysis. 
Quantification for ubiquitylation is shown at 15 mins time point.  
(B) Comparison of TNF induced NF-B activation in parental and RIPK1 KO MDA-MB-231 
cells. Cells were either left untreated or treated with TNF (10 ng/ml) for indicated times and 
lysates were analyzed by western blotting 
(C) The presence of cytokines in the culture media of parental and RIPK1 KO MDA-MB-231 
cells was determined by ELISA. Cells were stimulated with TNF for 6 hrs. Error bars 
represent SD. 
(D) TUBE affinity purification of lysates from WT and MIB1/2 DKO MDA-MB-231 cells pre-
treated with SM (100 nM) for 10 mins, followed by TNF (10 ng/ml) for the indicated time 
points. 
(E) TUBE affinity purification of lysates from reconstituted MDA-MB-231 cells. Expression of 
the indicated proteins was induced with Doxycycline (500 ng/ml) for 64 hrs followed by pre-
treatment with SM (100 nM) for 10 mins, after which TNF (100 ng/ml) was added for the 
indicated times. Quantification of ubiquitylated RIPK1 above the dotted line at 15 and 30 
mins. 
(F) Western blot analysis of reconstituted MDA-MB-231 cells. Prior treatment, expression of 
the indicated proteins was induced with doxycycline (500 ng/ml) for 60 hrs. Cells were either 
left untreated or treated with TNF (100 ng/ml) in presence or absence of SM (100 nM) for 30 
mins followed by MIB2 immuno-precipitation.  
(G) In vitro ubiquitylation assay using the indicated purified proteins. The presence of 
ubiquitylated RIPK1 was evaluated by immunoblotting the reaction with an anti-RIPK1 
antibody. 
Feltham et al., 2018 
 26 
 
Figure 6. MIB2 ubiquitylates the linker and the C-terminal portion of RIPK1 with 
different types of linkages. 
(A) UbiCRest analysis of ubiquitylated RIPK1 associated to complex-I. WT and MIB1/2 DKO 
MDA-MB-231 cells were treated with FLAG-TNF (0.8g/ml) for 10 mins, and complex-I was 
immuno-precipitated using FLAG-beads. Beads were aliquoted and treated with the indicated 
DUBs in parallel reactions for 30 mins at 37 °C. The ubiquitylation status of RIPK1 was 
analyzed by western blot.  
(B) MIB2 can target RIPK1 for ubiquitylation with K11-, K48- and K63-linked chains. The 
indicated constructs were co-expressed in HEK293T cells, and lysates were immunoblotted 
with an anti-RIPK1 antibody.  
(C) Schematic representation of all ubiquitylation sites of RIPK1 identified by mass 
spectrometry-based experiments. Each circle indicates an independent experiment. Green 
marks previously identified residues.  
(D) Schematic representation of the ubiquitylation sites of RIPK1 that are mediated by MIB2. 
Fold ubiquitin enrichment of RIPK1 sites in MIB2WT compared to MIB2F>A is shown. 
(E) diGly MS/MS spectra of K377 of human RIPK1 (precursor ion 688.00783+, error -0.58 
ppm, ion score 21.8). For clarity, only prominent fragment ions are marked.  
(F) Ubiquitylation of RIPK1 in complex-I. RIPK1 KO MDA-MB-231 cells reconstituted with 
either RIPK1WT or RIPK1K377R were treated with FLAG-hTNF for the indicated time-points, 
followed by FLAG immune-precipitation and western blot analysis. Quantification for RIPK1 
ubiquitylation is shown.  
(G) Immunoprecipitation of RIPK1 from RIPK1 KO MDA-MB-231 cells reconstituted with 
either RIPK1WT or RIPK1K377R. Quantification for RIPK1 phosphorylation is shown. 
 
 
Figure 7. MIB2 ubiquitylates RIPK1 at lysine K377 and K634 
(A-D) A homology model of human RIPK1 Death Domain (DD) (583-669) was generated by 
the SWISS-MODEL server. The PIDD DD (PDB 2OF5) was used as homology template. 
RIPK1 DD model was aligned to Fas DD in Fas/FADD complex structure (PDB code 3OQ9). 
Residues K604 and K634 are found at the interface between two RIPK1 DD (Type I and II 
Feltham et al., 2018 
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interfaces) (B, C), which should affect RIPK1 self-association if ubiquitinated. K634 also 
locates between RIPK1 DD and FADD DD (Type II interface) (C), which is predicted to 
directly affect the interaction if ubiquitylated. 
(E) DEVDase activity assay of RIPK1 KO MDA-MDA-MB-231 cells reconstituted with either 
RFP, RIPK1WT, RIPK1K377R or RIPK1K634R and treated with TNF/TAK1i for 3 hrs. Expression of 
RFP, RIPK1WT, RIPK1K377R or RIPKK634R was induced with doxycycline for 3 hrs. 
(F) FACS analysis of PI positive Ripk1 KO MDA-MB-231 cells reconstituted with either RFP, 
RIPK1WT, RIPK1K377R or RIPK1K634R and treated with TNF/TAK1i for 3 hrs. Error bars 
represent SD. 
(G) FACS analysis of PI positive MDA-MB-231 RIPK1 KO cells reconstituted with RIPK1WT or 
RIPK1K377R following MIB2 knockdown. Cells were stimulated with TNF/TAK1i for 3 hrs. Error 
bars represent SD. 
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Supplemental Text and Figures
Supplementary Figure S1. MIB2 is not required for TNF-induced NF-κB activation and cytokine 
secretion, Related to Figure 1  
(A) Western blot analysis of the indicated cell line subjected to RNAi-mediated knockdown of MIB1, 
MIB2 or MIB1/2. Cells were either left untreated or treated with TNF (10 ng/ml) for 15 mins. (B) The 
presence of cytokines in the culture media of the indicated cell line was determined by ELISA. Cells 
were subjected to siRNA knockdown of MIB2 or p65 followed by stimulation with TNF at increasing 
concentrations (0.2-5 ng/ml) for 6 or 24 hrs. Error bars represent SD. (C) Comparison of TNF induced 
NF-κB activation in parental and MIB1/2 DKO MDA-MB-231 cells. Cells were either left untreated or 
treated with TNF (10 ng/ml) for indicated times and lysates were analyzed by western blotting. (D) 
qRT-PCR analysis of mRNA from WT MDA-MB-231 and MIB1/2 DKO MDA-MB-231 cells. 
Relative A20 mRNA levels before and after 3 hrs of stimulation with 10 ng/ml TNF. (E-F) Comparison 
of TNF induced NF-κB activation in parental and MIB1/2 DKO HEK293 cells (E) or 786-0 cells (F). 
Cells were either left untreated or treated with TNF (10 ng/ml) for indicated times and lysates were 
analyzed by western blotting. (G) The presence of cytokines in the culture media of HeLa cells was 
determined by ELISA. HeLa cells were subjected to siRNA-mediated knockdown of MIB2 or p65 
followed by stimulation with TNF at increasing concentrations (0.2-5 ng/ml) for 6 or 24 hrs. Error bars 
represent SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2 
 
Supplementary Figure S2. MIB2 is required for TNF induced apoptosis, Related to Figure 2  
(A) Schematic depicting the sensitivities of various cell lines to negative regulators of RIPK1. (B) 
FACS analysis of PI positive HT1080 and 786-0 cells treated with TNF (10 ng/ml), SM (100 nM), 
TNF/SM or TNF/TAK1i (1 µM) for 24 hrs. Error bars represent SD. (C) Crystal violet cell survival 
assay of Kym1 and MDA-MB-231 cells treated with SM (100 nM) or TNF (10 ng/ml)/SM (100 nM) 
for 24 hrs. Error bars represent SD. (D) FACS analysis of PI positive 786-0 cells subjected to siRNA-
mediated knockdown of MIB2. Following RNAi-mediated knockdown, cells were treated with DMSO 
or zVAD-FMK (10 µM) for 1 hr followed by treatment with TNF/TAK1i for 48 hrs. Error bars 
represent SD.  (E) FACS analysis of PI positive HT1080 IkBSR cells in which MIB2 was knocked down 
by RNAi. Cells were treated with TNF (10ng/ml) for 24 hrs. Error bars represent SD. (F) FACS 
analysis of PI positive 786-0 cells subjected to siRNA-mediated knockdown of MIB2. Following 
RNAi-mediated knockdown, cells were treated with TNF (10 ng/ml) + CHX (10 µg/ml) for 24 or 48 
hrs. Error bars represent SD. (G) Cell death analysis by Celigo of PI positive HT1080 cells subjected to 
siRNA-mediated knockdown of MIB2. Following RNAi-mediated knockdown, cells were treated with 
DMSO, zVAD-FMK (10 µM) or RIPK1i-GSK’963 (100 nM) for 1 hr followed by treatment with 
TNF/SM. Error bars represent SD. (H) Cell death analysis by Celigo of PI positive 786-0 cells 
subjected to siRNA-mediated knockdown of MIB2. Following RNAi-mediated knockdown, cells were 
treated with DMSO, zVAD-FMK (10 µM) or RIPK1i-GSK’963 (100 nM) for 1h followed by treatment 
with TNF/SM. Error bars represent SD. (I) FACS analysis of Kym1 cells treated with control siRNA 
oligos, or two independent oligos targeting MIB2. (J) Clonogenic growth assay using Kym1 cells 
subjected to siRNA knockdown of MIB2. 64 hrs post siRNA, 1000 cells were re-plated and left to form 
colonies. Error bars represent SEM. (K) Proximity ligation assay between RIPK1 and caspase-8 
performed in Kym1 cells upon treatment with SM (100 nM) for 5 hrs or siRNA knockdown of MIB1, 
MIB2, MIB2/RIPK1 for 96 hrs. All samples were treated with zVAD-FMK (10 µM) in fresh medium 
16 hrs after transfection and then spiked with zVAD-FMK (10 µM) again at 48 hrs. (L) Western blot 
analysis of activated caspase-8 (p20 cleavage product) following siRNA knockdown of the indicated 
targets in Kym1 cells for 64 hrs. (M) DEVDase activity analysis of parental or TNF-R1 KO Kym1 cells 
subjected to siRNA-mediated knockdown of MIB2. Following RNAi-mediated knockdown, cells were 
lysed and caspase activity was measured. (N) DEVDase assay using extracts from SWISS-3T3 cells 
subjected to siRNA knockdown of Mib2. Following RNAi-mediated knockdown, cells were treated 
with TNF/SM in presence or absence of RIPK1i-GSK’963 (100 nM) for 24 hrs. Error bars represent 
SD. (O) Cell death analysis by Celigo of PI positive SWISS-3T3 cells subjected to siRNA knockdown 
of Mib2. Following RNAi-mediated knockdown, cells were treated with the indicated agents for 17 hrs. 
Error bars represent SD. 
 
 
 
 
 
 
 
 
 
 
Figure S3 
Supplementary Figure S3. MIB2 binds to oligomeric RIPK1, Related to Figure 3  
(A-E) The indicated constructs were co-expressed in 293T cells. Immuno-precipitation was performed 
and interaction was assessed via western blot. (F) Schematic representation and summary of the results 
regarding MIB2 binding and RIPK1 homo-oligomerization. Indicated are the oligomerization and 
MIB2 binding capabilities of the various deletion constructs. (G) In vitro binding assay with 
recombinant MIB2 and in vitro translated RIPK1. H) Western blot analysis of in vitro synthesized 
RIPK1 using the indicated antibodies. An asterisk indicates cross reactive bands. (I) Western blot 
analysis of in vitro synthesized RIPK1 treated with λ phosphatase as indicated.  (J) In vitro binding 
assay of the indicated constructs. Left panel: input proteins. Middle panel: binding assay. FLAG-
immuno-precipitation was performed and homo-oligomerization of in vitro synthesized RIPK1 proteins 
was assessed by Western blot. Right panel depicts the summary of the data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4 
 
Supplementary Figure S4. RIPK1 is a substrate for MIB2, Related to Figure 5  
(A) 786-0 cells were subjected to siRNA of MIB2 followed by TNF-induced complex-I immuno-
precipitation. Cells were treated with FLAG-hTNF (0.8 µg/ml) for 0, 5, 15 and 30 mins followed by 
FLAG immuno-precipitation and western blot analysis. (B) Comparison of TNF induced NF-κB 
activation in parental and RIPK1 KO 786-0 cells. Cells were either left untreated or treated with TNF 
(10 ng/ml) for indicated times and lysates were analyzed by western blotting. (C) Comparison of TNF-
induced activation of ERK, p38 and JNK in parental and RIPK1 KO 786-O cells. Cells were either left 
untreated or treated with TNF (10 ng/ml) for indicated times and lysates were analyzed by western 
blotting. (D) Comparison of TNF induced NF-κB activation in parental, RIPK1 KO and TNF-R1 KO 
Kym1 cells. Cells were either left untreated or treated with TNF (10 ng/ml) for indicated times and 
lysates were analyzed by western blotting. (E) Comparison of TNF induced NF-κB activation in 
parental and RIPK1 KO Jurkat cells. Cells were either left untreated or treated with TNF (10 ng/ml) for 
indicated times and lysates were analyzed by western blotting. (F) Untagged GFP, MIB1, MIB2WT, 
MIB2F>A or MIB2R2 was co-expressed with HA-Ub and untagged RIPK1 in 293T cells. HA-immuno-
precipitation was performed and ubiquitylation of RIPK1 was assessed via western blot. (G) Yeast-
two-hybrid assay screening the interaction of the RING finger of MIB2 (encoding amino acids 843-
1000) with 22 human E2s and 6 human Ub-conjugating E2 variants (TSG101, Uev1a, Uev1b, Mms2, 
Ube2v3, Ft1). 
 
 
  
Figure S5 
Supplementary Figure S5. RIPK1K377R mutation does not abrogate binding to MIB2, Related 
to Figure 6 
(A) RIPKWT and RIPK1K377R were co-expressed with the indicated constructs in 293T cells. HA-
immuno-precipitation was performed and ubiquitylation of RIPK1 was assessed via western blot. (B) 
FLAG MIB2 was co-expressed with untagged RIPK1WT or RIPK1K377R in 293T cells. FLAG-immuno-
precipitation was performed and interaction with RIPK1 was assessed via western blot. 
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Figure S6 
Supplementary Figure S6. Expression of RIPK1 mutants in MDA-MB-231 cells, Related to 
Figure 6  
Western blot analysis of lysates from parental and RIPK1 KO MDA-MB-231 cells reconstituted with 
either RIPK1WT, RIPK1K377R and RIPK1K377R were induced with doxycycline for 6 hrs.  
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Figure S7 
 
Supplementary Figure S7. MIB2 ubiquitylates RIPK1 at multiple lysine residues, Related to 
Figure 7 
(A-B) Ubiquitylation of RIPK1 in complex-I. RIPK1 KO MDA-MB-231 cells were reconstituted with 
either RIPK1WT or RIPK1K377R (A) or RIPK1K634R (B). Cells were subjected to RNAi-mediated 
knockdown of MIB2. 48 hrs later cells were treated with FLAG-hTNF (0.8 µg/ml) for the indicated 
time-points post 5 hrs doxocycline induction, followed by FLAG immune-precipitation and western 
blot analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplemental Experimental Procedures  
Resource Table  
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
α-RIPK1 (N-terminal) Cell Signaling  Cat#3493 
α-HA Roche  Cat#11867423001 
α-MIB2 Bethyl Laboratories Cat#A301-414A 
α-MIB1 Gift from Patricia J. 
Gallagher 
N/A 
α-CYLD Cell Signaling Cat#8462; D1A10 
α -SHARPIN Proteintech Cat#14626-1-AP 
α-HOIL Gift from Henning 
Walczak 
N/A 
α-HOIP Bethyl Laboratories Cat#A303-560A 
α-NEMO Santa Cruz Biotechnology Cat#sc-8330 
α-TRADD BD Biosciences Cat#610572 
 
α-cIAP1 Enzo Life Sciences  Cat#ALX-803-335-
C100 
α-TAK1 Cell Signaling Cat#4505 
α-TNF-R1 Abcam Cat#19139 
α-TNF-R1 Santa Cruz Biotechnology Cat#sc-8436 
α-ACTIN Sigma Cat#A5441 
α-P-p65 Cell Signaling Cat#3033 
α-p65 Cell Signaling Cat#8242 
α-IκBα Santa Cruz Biotechnology Cat#sc-371 
α-P-IκBα Cell Signaling Cat#2859 
α-P-p38 Cell Signaling Cat#9215 
α-p38 Cell Signaling Cat#9212 
α-P-JNK Cell Signaling Cat#4668 
α-JNK Santa Cruz Biotechnology Cat#sc-571 
α-P-ERK Cell Signaling Cat#9101 
α-CASPASE-8 - for WB - post IP MBL Cat#M032-3 
α-CASPASE-8 - for IP [C-20] Santa Cruz Biotechnology Cat#sc-6136 
α-CASPASE-8 for cleavage R&D Cat#AF1650 
α-FLAG [M2] Sigma  Cat#F3165 
α-Ub Dako Cat#Z0458 
α-PARP1 [F2] Santa Cruz Biotechnology Cat#sc-8007 
α-FLIP Enzo Life sciences  Cat#ALX-804-428-
C050 
α-GFP Santa Cruz Biotechnology Cat#sc-8334 
α-MYC Sigma Cat#M5546 
α-HSP90 Santa Cruz Biotechnology Cat#sc-7947 
α-A20 Cell Signaling Cat#5630 
α-TRAF2 Santa Cruz Biotechnology Cat#sc-876 
α-ERK Gift from Chris Marshall N/A 
α-pERK Sigma M8159 
Chemicals, Peptides, and Recombinant Proteins 
Enbrel Wyeth N/A 
Biotin-AHX-Ub-PA (UbiQ) Cat#UbiQ-076 
FLAG-hTNF Enzo Life Sciences  Cat#ALX-804-034-
C050 
FLAG-hTNF Gift from Henning 
Walczak 
N/A 
(5Z)-7-Oxozeaenol (TAK1 inhibitor) Tocris  Cat#3604 
zVAD-FMK Apex Bio Cat#A1902 
QVD Apex Bio Cat#A1901 
SM-164 Gift from Shaomeng 
Wang 
N/A 
LPS Invivogen Cat#TLRL-PEKLPS 
Ac-DEVD-AMC Cambridge Bio 
 
Cat#CAY14986 
Hoechst Thermo Scientific  Cat#33342 
Propidium iodide solution (PI) Sigma Cat#P4864 
MTT reagent Sigma  Cat#M5655 
Protein A/G agarose Thermo Scientific 20423 
Halt Protease and phosphatase inhibitor  Thermo Scientific 78443 
PR619 2B Scientific SI9619 
GSK’963 (RIPK1 inhibitor) Gift from GSK N/A 
Human TaqMan A20 Probe Hs00234713_m1 Thermo Scientific Cat#4331182 
Human TaqMan ACTIN Probe Hs01060665_g1 Thermo Scientific Cat#4331182 
Critical Commercial Assays 
RNAEasy Qiagen  Cat#74106 
QuantiTech reverse transcription Qiagen Cat#205314 
 
Duolink In Situ Detection Reagents Green Sigma DUO92014 
Experimental Models: Cell Lines 
HT1080IkB-SR Gift from O. Micheau 
(Dijon, France) 
N/A 
Kym1 Gift from John Silke 
(Melbourne, Australia) 
N/A 
HT1080 ATCC Cat#CCL-121 
MDA-MB-231 In house  N/A 
HEK293T In house N/A 
Flp-InTMT-RExTM-HEK293 Termo Scientific  Cat#R78007 
786-0 In house N/A 
SWISS-3T3 In house N/A 
Oligonucleotides 
shRNA Mib2 Thermo Scientific Clone ID: 
V3THS_324301 
siMIB2_1 [Hs_ZZANK1_4 (hMib2)] Qiagen Cat#SI00779688 
siMIB2_4 [hs_Mib2_4] Qiagen  Cat#SI04369778 
 
siMIB2_6 [hs_Mib2_6] Qiagen  Cat#SI05126436 
 
siALL*Control  Qiagen  Cat#1027281 
Recombinant DNA 
Cas9-plasmid Addgene Cat#41815 or 48138 
Mib2 cDNA Gift from Vanessa 
Redecke 
N/A 
pcDNA3 Thermo Scientific Cat#V79020 
Deposited Data   
http://dx.doi.org/10.17632/52t6f2m8k5.1   
Software and Algorithms 
CRISPR design http://crispr.mit.edu (Ran et al., 2013) 
CRISPR design http://www.addgene.org/cr
ispr/church/ 
(Mali et al., 2013) 
SAINT analysis http://saint-
apms.sourceforge.net/ 
(Choi et al., 2011) 
Swiss-Prot https://www.ebi.ac.uk/uni
prot 
 
Proteome Discoverer v1.4 Thermo Scientific Cat#IQLAAEGABSF
AKJMAUH 
Image Lab V5.2.1. Bio-Rad laboratories  
Sequence alignment http://benchling.com  
GraphPad Prism v6.0 http://www.graphpad.com
/ 
 
 
CONTACT FOR REAGENTS AND RESOURCE SHARING 
Further information and requests for reagents may be directed to Pascal Meier (pmeier@icr.ac.uk). 
 
Plasmids 
The MIB2 cDNA (kind gift from Vanessa Redecke) was altered by mutagenesis to correspond to 
Q96AX9-2 - MIB2_human (UniProt). All constructs used for transient transfection experiments were 
cloned into pcDNA3 mammalian expression vector (Invitrogen) and sequence verified. For generation 
of stable cell lines Lentiviral tet-On inducible vector pTRB3A1 was used and cells were selected in the 
presence of Blasticidin. 
 
RNA Interference, Transfections and Infections 
Unless otherwise indicated, all siRNA assays were performed using a total of 50 nM – 100 nM of 
siRNA. When multiple siRNAs were combined, each siRNA was used at 25 nM and control siRNA 
was used where required to balance siRNA concentrations so equal amounts were transfected. All 
siRNA transfections unless otherwise stated were performed using DharmaFECT4 transfection reagent 
(GE Healthcare) and Opti-MEM (Life Technologies). All siRNA transfections unless otherwise stated 
were performed using retro transfection and left for 40 hrs from the time of transfection to facilitate 
knockdown. Unless otherwise indicated siMIB2 refers to the combination of hs_ZZANK1_4 (25 nM) 
+ hs_MIB2_2 (25 nM) + hs_MIB2_4 (25 nM) + siCtrl (25 nM). For experiments where siMIB1 and 
siMIB2 are co-knocked down, siMIB2 refers to the combination of hs_MIB2_2 (25 nM) + hs_MIB2_4 
(25 nM) + siCtrl (50 nM) or siMIB1 (50 nM). For all ELISA experiments 5x105 cells were 
electroporated with 10 µl of 20 µM siRNA then seeded at 3x104 in 24-well plates for 48 hrs. 
Generation of lentiviral particles was conducted as described previously (Vince et al., 2008; Vince et 
al., 2007).  
Caspase-8 Cleavage Assays 
Cells were seeded in 6-well plates and treated as indicated. Cells were lysed in 200 µl of DISC lysis 
buffer supplemented with 2% SDS, protease and phosphatase inhibitors. Cell lysates were passed 
through 0.8 ml columns (Pierce) to shred genomic DNA. Proteins lysates were quantified before 
separating samples by SDS-PAGE using NuPAGE Novex 4-12% Bis-Tris 1.0 mm 12 well precast 
protein gels (Invitrogen) in MES buffer. Caspase-8 cleavage antibody [AF1650] (R&D) was used to 
detect cleavage products.   
 
Cell Death (FACS) and MTT assays 
Cells were plated in 96-well plates and retro siRNA transfection was performed for 40 hrs. Cells were 
treated as indicated in 150 µl for indicated times. Medium containing dead cells was transferred to a 
round bottom 96 well plate, live cells were trypsinized in 50 µl, live cells were harvested with 100 µl of 
medium containing 1 µg/ml PI with 2.5 mM CaCl2 and 2.5 µl/ml AnnexinV antibody (BD Biosciences) 
and combined with dead cells (total volume 300 µl). 96-well plate was analyzed by FACS using a plate 
reader. Data shown are from 5000 cells per condition. For CeligoS assays, 5 x104 786-O or HT1080 
cells were seeded in 96-well plates and 24 h later cells were treated as indicated for the indicated times. 
Hoechst (0.5 µg/ml) and PI (1 µg/ml) were added and the percentage of dead cells was measured using 
the CeligoS image cytometer (Nexcelon Bioscience). For MTT assays 5x104 cells were seeded in 24-
well plates. Cells were treated as indicated in 500 µl for indicated times, after which 50 µl of MTT 
reagent re-suspended in H20 to a concentration of 5 mg/ml was added to the cells and left to develop 
for 2 hrs. Media was removed and 500 µl DMSO added to solubilize the crystals. Absorbance was read 
on a spectrometer at 570 nm.  
 
Crystal Violet Cell Survival Assays 
Cells were seeded in a 6-well plate. The following day the indicated treatments were added in 2 ml of 
DMEM and the cells were left for 24 hrs in treated medium. Cells were fixed in 3.7% 
formaldehyde/PBS for 10 mins and stained with crystal violet/PBS for 10 mins. Colonies were either 
dissolved in 1 ml of 10% acetic acid and the absorbance read on a spectrometer at 595 nm.  
 
Clonogenic Assays 
Cells were seeded in a 6-well plate and retro siRNA transfection was performed. After 40 hrs (786-0) 
or 64 hrs (Kym1) cells were trypsinized, counted and 1000 viable cells were re-plated into a 6-well 
plate. The following day the indicated treatments were added in 2 ml of DMEM and the cells were left 
for approximately 9 days in treated medium. Cells were fixed in 3.7 % formaldehyde/PBS for 10 mins 
and stained with crystal violet/PBS for 10 mins. Colonies were either dissolved in 1 ml of 10% acetic 
acid and the absorbance read on a spectrometer at 595 nm, or the colonies were counted and recorded 
using Image J.     
 
Caspase activity assays (DEVDase) 
DEVDase assay was performed as previously described (Jaco et al., 2017). In brief, cells were plated in 
96-well plates and retro siRNA transfection was performed for 40 hrs. After treatment, medium was 
removed and 1 % DISC lysis buffer (20 mM Tris-HCL pH7.5, 150 mM NaCl, 2 mM EDTA, 1 % 
Triton X-100, 10 % Glycerol, H20) was added to each well. Plates were placed at -80 °C to aid cell 
lysis. Plates were thawed at room temperature for 15 mins, after which DEVDase assay mix was added 
to each well (NB: cell lysates were not cleared). The plates were wrapped in foil and the reaction was 
incubated at room temperature for up to 24 hrs. DEVDase activity was read at 380 nM excitation/460 
nM emission. 
 
TUBE Assays  
Cells were lysed in DISC lysis buffer (20 mM Tris-HCL pH7.5, 150 mM NaCl, 2mM EDTA, 1% 
Triton X-100, 10% Glycerol, H20) supplemented with protease inhibitors, 1 mM DTT, PR619 (10 µM), 
GST-TUBE (50 µg/ml; 50 µg TUBE/mg protein lysate). Cell lysates were rotated at 4 °C for 20 mins 
then clarified at 4 °C at 14,000 rpm for 10 mins. 20 µl GST beads were added and immuno-
precipitation was performed overnight. 4x washes in wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 
0.1 % Triton X-100, and 5 % glycerol) + PR619 (10 µM) were performed, and samples eluted by 
boiling in 50 µl 1x SDS loading dye. 
 
Homology Modeling 
A homology model of human RIPK1 Death Domain (DD, 583-669) was generated by the SWISS-
MODEL server using PIDD DD structure as the template (PDB code 2OF5). Then modeled RIPK1 DD 
structure was aligned to FAS DD in FAS/FADD complex structure (PDB code 3OQ9) to form a RIPK1 
DD/FADD DD complex structure. The alignment was performed by Coot and figures were made by 
PyMol. 
 
Complex-I/II Purification 
Complex-I/II purification was essentially performed as previously described (Jaco et al., 2017). In 
brief, cells were seeded in 15 cm dishes and treated as indicated using pre-warmed media containing 
3xFLAG-hTNF (0.8 µg/ml). After stimulation media was removed and plates were washed with ice 
cold PBS to stop stimulation and frozen at -80 °C. Plates were thawed and cells were lysed in DISC 
lysis buffer supplemented with protease inhibitors and PR619 (10 µM). Cell lysates were rotated at 4 
°C for 20 mins then clarified at 4 °C at 14,000 rpm for 10 mins. 20 µl of anti-FLAG M2 beads 
(SIGMA) were rotated with cleared protein lysates overnight at 4 °C. 0 hr sample: 0.8 µg/ml of FLAG-
TNF was added post-lysis. 4x washes in DISC buffer with PR619 (10 µM) were performed, and 
samples eluted by boiling in 50 µl 1x SDS loading dye. For complex-II purification cells were seeded 
in 10 cm dishes and treated as indicated in figure legends. Cells were lysed on ice as above. Cell 
lysates were rotated at 4 °C for 20 mins then clarified at 4 oC at 14,000 rpm for 10 mins. 20 µl of 
protein G sepharose (SIGMA) with Caspase-8 (C20) antibody (Santa Cruz Biotechnology) (1.5 µg 
antibody/mg protein lysate) were rotated with cleared protein lysates overnight at 4 °C. 4x washes in 
wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% Triton X-100, and 5% glycerol) were 
performed, and samples eluted by boiling in 50 µl 1x SDS loading dye. 
 
Ubiquitylation Assays 
0.4 µg of plasmids expressing HA-Ub or Myc-Ub was transfected into 293T cells in combination with 
the indicated constructs. Transfection was left for 16 hrs after which cells were lysed with DISC lysis 
buffer supplemented with protease inhibitors and PR619 (10 µM). Cell lysates were rotated at 4 °C for 
20 mins then clarified at 4°C at 14,000 rpm for 10 mins. 20 µl anti-HA beads (SIGMA) or 20 µl of 
protein G sepharose (SIGMA) + 3 µl anti-Myc were rotated with cleared protein lysates overnight at 4 
°C. 4x washes in wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% Triton X-100, and 5% 
glycerol) supplemented with PR619 (10 µM) were performed, and samples eluted by boiling in 50 µl 
1x SDS loading dye. 
 
In vitro Binding and Ubiquitylation Assay  
All constructs for in vitro translation assays were cloned into pcDNA3 and translated using the 
Promega TNT Coupled Reticulocyte Lysate System. For production of GST-tagged proteins, MIB2 
constructs were expressed from pGEX6p-1 in BL21(DE3)/pLysS strain and purified with GST beads. 
All in vitro binding assays were conducted in the presence of DISC buffer overnight at 4 °C. Beads 
were washed 4 times with the same buffer and protein complexes were eluted by boiling the beads in 
1x SDS loading dye. For the in vitro assay shown in Fig 5G, purified Strep-tagged MIB2 was 
incubated with recombinant GST-tagged full length RIPK1 (Abnova), E1 enzyme preloaded with Ub 
(Boston Biochem), UbcH5a (Boston Biochem) and ATP in Ub assay buffer (40 mM Tris-HCL pH 7.5, 
10 mM MgCl2, 0.6 mM DTT) at 37 °C for 90 mins. Reactions were stopped by adding SDS loading 
dye and samples were analysed by Western blot with the indicated antibodies.   
 
UbiCRest  
The UbiCRest analysis with linkage selective DUBs was performed essentially as previously described 
(Hospenthal et al., 2015). Briefly, the release fraction (see above) was incubated with the following 
DUBs: 1 µM OTULIN, 0.2 µM OTUD1, 1 µM CEZANNE, 0.2 µM OTUB1, 1.5 µM USP21, 0.5 µM 
vOTU. The reaction was conducted in the presence of 1 mM DTT for 30 min at 37 °C. Reactions were 
stopped with loading buffer, and the ubiquitylation status analyzed by western blotting. 
 
Proximity Ligation Assay 
PLA was performed according to the manufacturer’s protocol using the Duolink Detection Kit 
(SIGMA). Cells were examined with a confocal microscope (objective x 40, Zeiss LSM 710).  
 
Directed Yeast Two-Hybrid Assays  
The yeast strain Y2HGold (Clontech) was co-transformed with pGBT9-MIB2 (encoding amino acids 
843-1000) as a bait and the respective prey plasmids encoding 22 human E2s and 6 human Ub-
conjugating E2 variants. Positive transformants were selected on minimal SD-Leu-Trp medium 
(Formedium). Three single colonies for each bait and prey co-transformation were patched out on fresh 
SD-Leu-Trp plates and grown for 2 days at 30 °C. Each patch was re-suspended in 180 µl of sterile 
water in a 96 well plate and plated in replicate onto non-selective (SD-Leu-Trp) or selective medium 
(SD-Leu-Trp-His, containing 5 mM of 3-amino-1,2,4-triazole (3-AT, Formedium)). Yeasts were 
incubated at 30ºC for 1 week. The E2s/UEVs library was kindly provided by Rachel Klevit. 
 
qRT-PCR  
qRT-PCR was performed as previously described (Morris et al., 2016), with some modifications. 
MDA-MB-231 parental and MIB1/2 DKO were treated with TNF (10 ng/ml) for 3 hrs and immediately 
frozen. qRT-PCR was performed using Taqman gene expression mastermix (Thermo Fisher Scientific) 
and the QuantStudio 6 Flex Real-Time PCR System. The amount of mRNA detected was normalized 
to control ACTIN mRNA values. The relative ΔCt sample/ΔCtr Actin ratios of WT controls were set at 
100%, and the fold differences were calculated using the ΔΔCt method.   
 
Mass Spectrometry  
Prior to mass spectrometry analysis of RIPK1 interactors, eluted protein complexes were digested with 
Trypsin and peptides were purified using C18 Microspin columns (Harvard Apparatus) according to 
the manufactures instruction. LC-MS/MS analysis was performed on a dual pressure LTQ-Orbitrap 
mass spectrometer (Thermo Scientific), which was connected to an electrospray ion source (Thermo 
Scientific). Peptide separation was carried out using an easy nano-LC systems (Proxeon Biosystems) 
equipped with an RP-HPLC column packed with C18 resin (Magic C18 AQ 3 µm; Michrom 
BioResources). A 0.3 µl/min linear gradient from 96 % solvent A (0.15 % formic acid, 2 % 
acetonitrile) and 4 % solvent B (98 % acetonitrile, 0.15 % formic acid) to 40 % solvent B over 40 min. 
The data acquisition mode was set to obtain one high-resolution MS scan in the FT part of the mass 
spectrometer at a resolution of 60,000 FWHM followed by MS/MS scans in the linear ion trap of the 
20 most intense ions. Raw files were converted to the mzXML format, and searched against the human 
swissprot protein database. Further data processing including SAINT was carried out as described 
previously (Choi et al., 2011). For the identification of ubiquitylated sites on RIPK1 by MIB2, 293T 
cells were transfected with 3xHA-RIPK1, MIB2 and Ub or 3xHA-RIPK1, MIB2F>A and Ub for 48 
hrs. After lysis with DISC lysis buffer in the presence of protease inhibitors and PR619, HA affinity 
purification was performed. Bound complexes were eluted with 5 % formic acid and then submitted for 
analysis by LC-MS/MS using a tryptic digestion workflow. Specific accurate mass (+/- 10 ppm) and 
retention time (AMRT) profiles were determined for the peptides of interest, accounting for the 
following variable modification states: unmodified and diGly-modification of lysine. Additionally, the 
sum value of four RIPK1 peptides was calculated relative to the data from the RIPK1 sample. The four 
peptides were selected as proxies to indicate the level of RIPK1 in the two samples. LC-MS/MS 
analysis of ubiquitylated peptides was performed after immuno-precipitation. Elutes were dried in 
vacuo and reconstituted in 50 mM triethylammonium bicarbonate. Samples were then reduced with 5 
mM tris(2-carboxyethyl)phosphine, free cysteines were alkylated with 10 mM chloroacetamide or 
chloroacetic acid and protein was digested with trypsin. For the targeted analysis of residue K377, a 
second digestion was performed using endoproteinase Glu-C. The resulting peptides were analysed by 
direct injection on an Agilent 1200 nanoLC (Agilent Technologies) in-line with an LTQ Velos Orbitrap 
mass spectrometer (Thermofisher Scientific) with the following modifications: Peptides were resolved 
over 30 mins using a linear gradient of 96:4 to 50:50 buffer A:B (buffer A: 1% acetonitrile/3 % 
dimethyl sulfoxide/0.1 % formic acid; buffer B: 80 % acetonitrile/3 % dimethyl sulfoxide/0.1 % formic 
acid) at 250 nL/min. The ion at 401.922718 m/z was used for FT-MS internal lock mass calibration. 
Peak lists were extracted using Proteome Discoverer v1.4 and interrogated using Mascot v2.3 against 
the Swissprot 2015_04 Homo Sapiens subset database (20,273 sequences) customized to include 
construct sequences as required. Residual Ub signatures GG and LRGG were included as variable 
modifications at lysine residues. 
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